Biography
Steve Kornguth took his BA at Columbia College in New York City and his Ph.D. in biochemistry at the University of Wisconsin- Madison. He was Professor of Neurology and of Biomolecular Chemistry at the University of Wisconsin between 1962 and 1998. His research during this period related to neural development, biological basis of neurological disorders, autoimmune diseases and development of binding agents and platforms for biological threat agent sensors and magnetic resonance image contrast materials. In 1998 he moved to Texas and was Director of the Center for Strategic and Innovative Technologies and Associate Director of the Institute for Advanced Technology at the University of Texas-Austin until 2012. He is currently Senior Research Fellow in the Department of Kinesiology and Health Sciences at The University of Texas-Austin. He directed the Biological and Chemical Countermeasures Program and the Sustaining and Enhancing High OpTempo Performance of Soldiers for the University of Texas. Dr. Kornguth published over 130 articles in peer reviewed journals, including patents and is the editor of books in the areas of biodefense and of human performance.
Research Interest
Neurology and of Biomolecular Chemistry neural development, biological basis of neurological disorders, autoimmune diseases and development of binding agents and platforms for biological threat agent sensors and magnetic resonance image contrast materials, biodefense and of human performance.
Biography
Andrew P. Goldberg, MD is Professor of Medicine, Head, Division of Gerontology and Geriatric Medicine, at the University of Maryland School of Medicine (UMSOM). He is Principal Investigator of the UMSOM Claude Pepper Older Americans Independence Center and NIA training program in exercise, nutrition and metabolism in aging, and Co-Director of the UMSOM Center for Research on Aging. Dr. Goldberg leads clinical and translational research examining the whole body, adipose, muscle and genetic mechanisms underlying the cardiometabolic effects of weight loss with and without aerobic exercise training on lipid and glucose metabolism and functional capacity in obese older people with diabetes, metabolic syndrome, stroke and ICU survivors. The goals are to understand mechanisms of disease, and develop novel exercise rehabilitation and dietary interventions to transform health care practices to reduce risk for complications of chronic disease and disability in older adults. He has published >200 peer-reviewed manuscripts, and mentored >60 pre- and post-doctoral trainees and junior faculty in clinical aging, exercise and metabolism research. He is nationally recognized for his achievements in geriatrics with award of the 2008 Joseph T. Freeman Award from The Gerontological Society of America and the 2009 Master Teacher Award in Geriatric Medicine and Gerontology from State University of New York Downstate Medical Center.
Research Interest
Gerontology and Geriatric Medicine, exercise, nutrition and metabolism in aging, Research on Aging. clinical and translational research examining the whole body, adipose, muscle and genetic mechanisms underlying the cardiometabolic effects of weight loss with and without aerobic exercise training on lipid and glucose metabolism and functional capacity in obese older people with diabetes, metabolic syndrome, stroke and ICU survivors. The goals are to understand mechanisms of disease, and develop novel exercise rehabilitation and dietary interventions to transform health care practices to reduce risk for complications of chronic disease and disability in older adults, clinical aging, exercise and metabolism research.
Biography
Luigi G Martini is Professor of Pharmaceutical Innovation at King’s College London where he is the UK’s first and only Industrial Pharmacist teaching practitioner providing an important link between Industry and Academia. His research interests include personalised medicine, drug delivery systems and medical device engineering. Heconsults for global companies and regulatory agencies in Europe and the Middle East, recently being invited to participate in European Parliament debates and appointed to the REF2014 sub-panel for Pharmacy, Dentistry, Nursing and Allied Healthcare professionals in 2011. Whilst at GlaxoSmithKline Pharmaceuticals, Professor Martini was Senior Director of Pharmaceutical Development for Emerging Marketshere he was responsible for developing affordable medicines for the BRIC economies. Hedeveloped and commercialised the DiffCORE technology launched in the USA as Lamictal XR,and was instrumental in embedding Quality by Design principles in GSK’s main development and manufacturing sites. Professor Martini is a PhD Pharmacist from Manchester University specialising in Drug Deliverywith a MBA from the University of Liverpool, specialising in SME businesses. Professor Martini was a Visiting Pharmacy Professor at John Moores University of Liverpool (2006-2011) and designated a Fellow of the Royal Pharmaceutical Society in 2008.
Research Interest
Personalised medicine, Drug delivery systems and Medical device engineering